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Available online 30 January 2012Opsonophagocytosis is the primary mechanism for the clearance of Group B Streptococcus
(GBS) by the host, and levels of opsonic antibodies may correlate with protection in preclinical
models. A killing-based opsonophagocytosis assay (OPA), can be used to determine the func-
tional activity of vaccine-induced GBS-specific antibodies. The assay, which measures the
number of bacterial colonies surviving phagocytic killing in the presence of specific antibodies
and complement, is rather expensive, time-consuming and poorly standardized.
Here we describe a rapid, sensitive and reproducible fluorescent OPA assay (fOPA) based on
flow cytometry analysis (FACS), which allows internalized bacteria to be distinguished from
those associated to the plasma membrane of phagocytic cells. Fixed GBS were labeled with
pHrodo™, a fluorescent dye which dramatically increases the emitted fluorescence at the acid-
ic conditions present in the phagocytic endosomal compartment. Labeled bacteria were incu-
bated with HL-60 cells differentiated to phagocytes, antibodies and complement, and then
analyzed by FACS. A further improvement to our method, allowing to reduce assay variability, con-
sisted on a step of selection of effector cells among the HL-60 population.
Analysis of sera from mice immunized with different GBS vaccines revealed comparable sensi-
tivity and specificity with the traditional killing OPA assay (kOPA), and a good correlation be-
tween the fluorescent signal of bacteria internalized by HL-60 phagocytes and killing.
Remarkably, the pHrodo-based approach reduced the variability observed with other fOPA as-
says. The obtained data indicate the proposed fOPA as a reliable and useful tool for functional
antibody assessment.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. Keywords:
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Vaccine1. Introduction
Streptococcus agalactiae also referred to as Group B
Streptococcus (GBS), is one of the most common causes of
life-threatening bacterial infections in infants. Neonatal GBS in-
fections can result in pneumonia, sepsis, meningitis and, in
some cases, death (McCracken, 1973; Ferrieri, 1985; Gibbs et
al., 2004). The introduction in the United States of guidelines
for neonatal GBS disease prevention, first issued in 1996 and
updated in 2002 and 2010, recommending universal screeningx: +39 0577 249314.
. Fabbrini).
Y-NC-ND license. of pregnantwomen and intrapartum antimicrobial prophylaxis
to carriers, was associatedwith a decline in the incidence of the
Early Onset Disease, (Boyer et al., 1983a,b; Gibbs et al., 1994;
Moore et al., 2003; Law et al., 2005), but has not eradicated
GBS disease in infants (Schuchat, 2000; Phares et al., 2008).
GBS is still a public health concern and the introduction of ad-
ditional prevention and therapeutic strategies is highly desir-
able. During the last two decades, polysaccharide-protein
conjugate vaccines against GBS have been extensively studied
in preclinical and human clinical studies (Baker et al., 1999,
2000, 2003a,b, 2007; Lancaster et al., 2011; Heath, 2011).
An obstacle to the development of vaccines against GBS is
the difficulty of conducting clinical efficacy trials, because of
the relatively low incidence of neonatal GBS disease. A
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the development of an effective functional antibody assay
as in vitro correlate of protection. The most commonly used
method to assess functional antibodies to GBS in post-
immunization sera is the in vitro killing-based opsonophago-
cytosis assay (kOPA) that mimics the in vivo process of killing
by host effector cells, following opsonization by specific anti-
bodies (Baltimore et al., 1977; Edwards et al., 1979;
Guttormsen et al., 2008). This assay can constitute a viable
surrogate of the effectiveness of a GBS vaccine, as passive
protection of mice by sera from individuals immunized with
GBS polysaccharide-based vaccines correlated with high
functional antibody titers measured by OPA (Baltimore et
al., 1981; Kasper et al., 1996; Brigtsen et al., 2002). However,
bacterial growth, colony plating and counting are time and
resource consuming steps and standardization presents chal-
lenges due to the source and quality of effector cells and to
the variability associated with plating and colony counting.
Although cultured phagocytes (differentiated HL-60 cells)
can be used in place of human peripheral polymorphonuclear
leukocytes (PMNs), as a less variable neutrophil source
(Romero-Steiner et al., 1997; Guttormsen et al., 2008,), the
fraction of HL-60 cells differentiated to active phagocytes
varies, representing a further source of variability.
Fluorescence based OPAs can limit the effort and variabil-
ity associated with plating and counting of surviving bacteria
(Plested and Coull, 2003; Guttormsen et al., 2009; Simons,
2010,). These assays use bacteria labeled with fluorophores,
such as fluorescein-derivatives (dicarboxyfluorescein, dihy-
drodichlorofluorescein, Oregon green), rhodamine or Alexa
Fluor derivatives (Rodríguez et al., 2001; Guttormsen et al.,
2009) and are rapid and efficient for large scale testing of
sera. However, these approaches do not distinguish between
adherent and internalized bacteria.
We developed a new flow cytometry based OPA that allows
discriminating between adherent and internalized bacteria
through the use of pHrodo™, a new pH sensitive fluorogenic
dye. Bacteria conjugated to pHrodo™ show a very low fluores-
cent signal at the neutral pH present on the cell surface, but
emit a bright red fluorescence in the acidic environment of
phago-lysosomes. This level of discrimination eliminateswash-
ing and quenching steps that are necessary with other non pH-
dependent indicators of bacterial uptake. Moreover the fOPA
here described takes advantage of the introduction of specific
markers of HL-60 differentiation to neutrophils, which allow
keeping under control the variability of effector cells.
The method was evaluated for sensitivity and specificity,
by testing a panel of sera from mice immunized with differ-
ent GBS glycoconjugate vaccines against polysaccharide Ia.
kOPA titers were compared with fOPA titers, and a confocal
microscopy analysis was conducted to study bacterial locali-
zation inside neutrophils, in the presence or in the absence
of specific antibodies and complement.
2. Materials and methods
2.1. Bacterial strains
GBS strains 515 (serotype Ia) (Baker et al., 1982) and
COH1 (serotype III) (Wessels et al., 1992) were used in this
work. Bacteria were grown in Todd–Hewitt Broth (THB) toan optical density at 600 nm (OD600 nm) of 0.45. Ten percent
glycerol was added to the culture before dispensing 1 ml ali-
quots in cryo-vials for flash freezing in a 95% ethanol-dry ice
bath. Frozen cultures were kept at −70 °C until use.
2.2. Antisera
OPAs were performed with rabbit and mouse sera. Rabbit
sera were raised by immunizing one animal with three doses
of monovalent CRM197-conjugated polysaccharide Ia, Ib and
III in presence of aluminum hydroxide (Alum). Mouse sera
were pooled from animals immunized with a GBS vaccine
composed by polysaccharide Ia, Ib and III conjugated to
CRM197, formulated with Alum or MF59 (Podda, 2001).
Animal treatments were performed in compliance with
the Italian laws and approved by the institutional review
board (Animal Ethical Committee) of Novartis Vaccines and
Diagnostics, Siena, Italy.
2.3. Bacterial labeling with pHrodo™
Bacteria were grown in THB to OD600 nm=0.6, washed
twice with Phosphate Buffered Saline (PBS, pH 7.2–7.4,Gibco)
and suspended in half volume of PBS-0.08% paraformaldehyde
(PFA, Sigma). Cells were incubated at 37 °C for 30 min and kept
at 2–8 °C in PBS-0.08%PFA. Immediately before labeling, cells
were washed with PBS, suspended at 20 mg (wet weight)/ml
using a freshly prepared 100 mM SodiumHydrogen Carbonate
solution pH 8.5 (Merck) and split into aliquots of 750 μl.
A 10 mM stock solution of PHrodo™ Succinimidyl Ester
(Invitrogen) in dimethyl sulfoxide (Sigma) was diluted in
the bacterial suspension at a final concentration of 0.1 mM.
Each sample was incubated for 45 min at room temperature
in the dark and then added with 750 μl of Hank's Balanced
Salt Solution with Ca2+ and Mg2+ (HBSS, Gibco), then spin
down with a bench top centrifuge for 60 s at 14,000×g. The
supernatant was aspirated and the pellet suspended in
HBSS and stored in the dark at 4 °C for two months. Bacterial
labeling was evaluated by FACS. The maximal fluorescence
emission of pHrodo™ labeled GBS was 585 nm. The absolute
concentration of labeled bacteria was determined by using
TruCOUNT tubes (BD pharmingen). The beads contained in
each tube were suspended in 100 μl of PBS and added to
100 μl of bacteria diluted 1/100 in PBS. The absolute cell count
(N) was calculated using the following equation: N=(number
of events in region containing bacteria) (number of beads per
test )/(no. of events in absolute count beads region), where
the number of beads per test was provided by BD Pharmingen
together with TruCOUNT Absolute Count Tubes.
2.4. Binding assays
Labeled bacteria were counted by FACS using truCount
Tubes and dispensed in 96 microtiter plates at 5×105 cells/
well. When live bacteria were tested, 1 ml aliquot of frozen
cells (OD600 nm: 0.45–0.5) was thawed at room temperature,
diluted in 9 ml of PBS and centrifuged at 3000 rpm for
10 min. The pellet was suspended in 20 ml of HBSS and dis-
pensed in plates (100 μl/well) in order to obtain 5×105 bacte-
ria/well. The plate was centrifuged; the pellet was suspended
in 100 μl of HBSS-1% normal rabbit serum and incubated for
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bated for 1 h at 4 °C in 100 μl of preimmune or immune sera
previously diluted 1/50 up to 102,400 in HBSS. After centrifuga-
tion and washing with 200 μl of PBS-0.1% Bovine Serum Albu-
mine (BSA, Sigma), samples were incubated for 1 h at 4 °C with
50 μl of Alexa Fluor 647 F(ab′)2 fragment of goat anti mouse
IgG (H+L) (Invitrogen) diluted 1/200 in PBS-0.2% BSA. Cells
were spun down by centrifugation, washed twice with PBS and
suspended in 130 μl of PBS. Fluorescence in the 96 well plates
was measured with FACS CantoII flow cytometer (BD Biosci-
ences, San Jose, CA), equipped with a 96-well plate loader.
2.5. Growth and differentiation of HL-60 cells
HL-60, a promyelocytic leukemia cell line, was obtained from
the American Type Culture Collection (CCL-240) and was main-
tained in RPMI 1640 glutamax (Invitrogen), supplemented
with 10% heat inactivated Fetal Bovine Serum (FBS, HyClone).
Cells were grown and differentiated to neutrophils in growth
medium supplemented with 0.78% Dimethyl Formamide (DMF,
Sigma), according to Romero-Steiner et al. (1997).
2.6. Killing-based opsonophagocytosis assay (kOPA)
The reaction was performed in 96 well polypropylene mi-
crotiter plates (Nunc), in a total volume of 125 μl HBSS. For
each reaction mixture, heat inactivated (56 °C for 30 min)
test serum (12.5 μl), GBS bacteria (25 μl), differentiated HL-
60 cells (75 μl) and baby rabbit complement (12.5 μl, Ceder-
lane) were added using a multichannel pipette. Control reac-
tions were performed in the presence of heat inactivated
baby rabbit complement or in the absence of antibodies or ef-
fector cells. Further negative controls were performed with
preimmune or mock immunization sera.
For each serum sample, six dilutionswere tested. The bacte-
rial suspensionwas prepared by directly diluting frozen aliquot
stocks. One ml aliquot of frozen bacteria (OD600 nm: 0.45–0.5)
was thawed at RT, diluted in 9 ml of PBS and centrifuged at
3000 rpm for 10 min. The pellet was suspended in an appropri-
ate volume of HBSS in order to obtain a final concentration of
~600 CFU/μl (~6×10 exp 4 CFU/well”). Bacteria were then di-
luted 1/2 in HBSS+% normal rabbit serum (Sigma) and dis-
pensed in plates. The effector cells to GBS cells ratio varied
from 25:1 to 40:1. The reaction plate was incubated for 1 h at
37 °Cwith shaking at 300 rpm by a Thermomixer (Eppendorf).
T0 reactions were diluted 1/100 in sterile water by the aid of
an electronic multichannel pipette. T60 reactions were diluted
1/20 and 1/200 in sterile water. Tenmicroliters of each dilution
were then plated in trypticase soy agar plate+5% blood sheep
(Particle Measuring Systems) and plates were incubated over
night at 37 °C+5% CO2 in order to determine bacterial–counts
at T0 and T60.
The OPA titer was expressed as the reciprocal serum dilu-
tion leading to 50% killing of bacteria, and percent of killing
was calculated as follows: killing (%)=[(mean CFU at T0−
mean CFU at T60)/mean CFU at T0] 100.
2.7. Fluorescent-based opsonophagocytosis assay (fOPA)
The reaction was performed in 96 well polypropylene mi-
crotiter plates (Nunc) in a total volume of 125 μl. Heatinactivated serum samples (12.5 μl), 25 μl of pHrodo™ la-
beled bacteria (1×107 bacteria/well) 75 μl of differentiated
HL-60 cells (1×106 cells/well) and 12.5 μl of 10% baby rabbit
complement were mixed. Positive and negative controls fol-
lowed the same scheme as for the kOPA. The plate was incu-
bated at 37 °C for 30 min and shaking (600 rpm). After
incubation, the plate was centrifuged at 1300 rpm for 5 min
at 4 °C, the supernatant was discarded and the pellet was
washed with 200 μl of PBS. A mixture of LIVE/DEAD® Fixable
Aqua Dead Cell Stain Kit for 405 nm excitation (Invitrogen)
(final concentration 0.5 μg/ml), V450-anti-human CD11b (BD
Horizon, final concentration 4 μg/ml) and FITC-anti-human
CD35 (BD Pharmingen, final concentration 2.5 μg/ml) were
added to each well for a total volume of 50 μl. The plate was in-
cubated for 30 min at 4 °C in the dark. After washing with PBS,
cells were suspended in 130 μl of PBS and samples were ana-
lyzed by FACS Canto II flow cytometer equipped with High
Throughput System custom refrigerated at 2–8 °C.
Phagocytosis was expressed as: A) Phagocytic activity:
mean fluorescent intensity (MFI); B) Percentage of phagocy-
tosis: (number of cells taking up particles)/(total cell num-
ber analyzed).
fOPA titers were calculated as the reciprocal of the serum
dilution corresponding to the cut off value (twice the mean
phagocytic activity in negative controls).
2.8. FACS analysis
Samples were acquired on FACS Canto II flow cytometer
equipped with 3-laser system (405, 488, 633 nm), eight
color configuration and BD FACS Diva™ v6.1.3 software. The
cytometer was checked daily by the Rainbow set up beads
(BD Biosciences). The compensation matrix was performed
by anti-mouse IgK/negative control (FBS) Compensation Par-
ticles Set (BD Biosciences) following manufacturer recom-
mendations. BD CompBeads were stained as compensation
controls for V450 anti-human CD11b and for FITC anti-
human CD35, while pHrodo™ labeled bacteria were used as
phycoerythrin (PE) fluorescence to calculate the compensa-
tion matrix. The compensation values were calculated auto-
matically by DiVa™ software. The BD High Throughput
Sampler (HTS) System was used to run the plate samples. A
total of 10,000 events were collected from each sample
gated on live cells.
Forward scatter and Side scatter were acquired on a linear
scale and fluorescence was acquired on a logarithmic scale. PE
and fluorescein isothiocyanate (FITC) were excited using
488 nm laser and the emission of fluorescence was collected
using 585/42 nm and 530/30 nm filters, respectively. V450
and LIVE/DEAD Fixable Aqua were excited by 405 laser and
fluorescence emission was collected with 450/50 nm and
510/50 nm DF filters. After acquisition, all data were exported
as Flow Cytometry Standard format 3.0 files (FCS files) and an-
alyzed by FlowJo (Mac-Version 9.1; Treestar US, Ashland, OR).
2.9. Confocal microscopy
Differentiated HL-60 cells were dispensed in 96 microtiter
plates and incubated with labeled bacteria for 30 min in the
presence of specific or unrelated serum and baby rabbit com-
plement, under the same conditions and using the same
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
M
ea
n 
Fl
uo
re
sc
en
t I
nt
en
si
ty
 (M
FI)
Sera dilutions
Live GBS (PS Ia-CRM197 + Alum)
Labeled GBS (PS Ia-CRM197 + Alum) 
Live GBS (preimmune)
Labeled GBS (preimmune)
Fig. 1. Flow cytometry analysis of labeled GBS bacteria. PHrodo™ labeled or live-unlabeled GBS Ia cells were incubated with mouse sera against GBS Capsular
polysaccharide Ia-CRM197 conjugate and a secondary anti-mouse antibody Alexa Fluor 647 conjugate, followed by FACS analysis.
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were washed twice with PBS (centrifuging the plate at
900 rpm for 5 min at 2–8 °C) and fixed with 4% PFA in PBS
for 5 min at 2–8 °C. After washing, bacteria were pelleted by
centrifugation at 900 rpm for 5 min. The plasma membrane
was then stained by incubating cells for 30 min at 4 °C with
100 μl of Alexa Fluor 488-phalloidin (0.16 μM, Molecular
Probes) solution or concanavalinA-FITC (Sigma) solution in
PBS (2 μg/ml). After washing, cells were suspended in 10 μl
of SlowFade Antifade kit (Molecular Probes) and mountedFig. 2. Gating strategy to analyze fluorescent OPA by FACS. (A) Discrimination betwe
forward scatter(FSC) and side scatter (SSC). (C) Discrimination of aggregates from si
tification with specific markers of HL-60 cell differentiation (anti-CD35 and anti-CD
perimental (in red) and negative control (in blue) samples.on a glass slide. Images were acquired on a Zeiss LSM 710
laser scanning confocal microscope.2.10. Data analysis
Each experiment was performed in triplicate. Data are
represented as mean ± SD. Correlations were analyzed by a
linear regression model. Fitting was analyzed with the sup-
port of a statistical software (GraphPad Prism 5).en live (gated region) and dead HL-60 cells. (B) Selection of HL-60 cells using
nglets using side scatter-W versus side scatter (SSC-W). (D) Neutrophil iden-
11b). (E) Histogram overlay showing the fluorescence shift between the ex-
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Fig. 3. Improvement of assay performance by introducing markers of HL-
60cell differentiation. Histograms show the fluorescent intensity of negative
and positive samples collected from fOPA performed with (A) and without
(B) antibodies against CD11b and Cd35 receptors.
Fig. 4. Opsonophagocytosis results using pHrodo™ labeled GBS type Ia. Differentiat
tions of pHorodo™ labeled GBS cells preincubated with buffer (w/o serum) or with
lated with Alum (immune serum). Reaction was performed in the presence of 10%
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3.1. Fluorescent labeling of bacteria
The amine-reactive succinimidyl ester of pHrodo™ dyewas
used to label paraformaldehyde (PFA) fixed bacteria via amine
groups present on the bacterial cell wall. To optimize bacterial
labeling, PFA fixed bacteria were first incubated with 0.1 mM
up to 0.9 mM concentrations of pHrodo™. A dye concentration
of 0.1 mM, yielded the highest ratio between themean fluores-
cence intensities of the positive and the negative controls (data
not shown) was chosen for further use.
To assess whether the fixation or conjugation steps al-
tered the integrity of target antigens, labeled GBS Ia bacteria
were compared with live bacteria for reactivity with a pool
of mouse sera specific for polysaccharide Ia using flow cy-
tometry analysis. As shown in Fig. 1, comparable dose depen-
dent antibody binding was observed for live and labeled
bacteria, while incubation with pre-immune sera did not re-
sult in any binding. A correlation coefficient (R2) of 0.95
was obtained for the linear regression derived by plotting
the dose dependent fluorescent signals measured for live
and labeled bacteria. The data indicated that the integrity of
target antigens was maintained after pHrodo™ labeling.3.2. Flow cytometry-based assay set up
Labeled bacteria were pre-incubated with heat inactivated
rabbit serum specific for polysaccharide Ia, followed by HL-
60 derived neutrophils and baby rabbit serum as source of
complement, as described in the Materials and methods
section. To reduce assay variability, fluorescently labeled
anti-CD35 and anti-CD11b antibodies were introduced as spe-
cific markers of HL-60 cell differentiation to phagocytes.
Furthermore, the amine reactive dye LIVE/DEAD® was used
to discriminate between live and dead HL-60 cells. This dye
can permeate compromised membranes of necrotic cells anded HL-60 cells were incubated for 30 min at 37 °C with different concentra-
a rabbit serum against GBS capsular polysaccharide Ia-CRM conjugate formu-
active or heat inactivated (HI) rabbit serum as source of complement.
1 2
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Fig. 5. A) Confocal microscopy of neutrophils interacting with pHrodo™ la-
beled bacteria. Differentiated HL-60 cells were incubated for 30 min at
37 °C in the presence of baby rabbit complement with GBS Ia pHrodo™ la-
beled bacteria pre-treated with a mouse serum against GBS PS Ia-CRM197.
After washing, cells were fixed with 4% paraformaldeyde and plasma mem-
brane of phagocytes was stained with Alexa Fluor 488-phalloidin. Panels A1
and A2 show respectively the plasma membrane of neutrophils in green and
internalized bacteria in red. The bright field image in panel A3 show bacteria
internalized and outside neutrophils (arrows) and merged images are
shown in panel A4. B) Differentiated cells were incubated for 30 min at
37 °C in the presence of baby rabbit complement with GBS Ia pHrodo™ la-
beled bacteria pretreated with a mouse serum against GBS PS Ia-CRM197
(B1) or uncorrelated serum (B2). After washing, cells were fixed with 4%
paraphormaldeyde and cellular and bacterial wall were stained with Alexa
Fluor 488-phalloidin.
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Fig. 6. Effect of temperature on the opsonic activity. Differentiated HL-60
cells were incubated for 30 min at 37 °C or 4 °C with different concentrations
of pHrodo labeled GBS Ia bacteria preincubated with a rabbit immune serum
against GBS capsular polysaccharide Ia-CRM conjugate (formulated with
Alum) in the presence of 10% active rabbit serum as source of complement.
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in a more intense fluorescent staining of dead cells compared
to live cells where only surface free amines are available.
After incubation, samples were analyzed by flow cytome-
try. Live HL-60 cells were first gated based on LIVE/DEAD®
(Fig. 2A) and then based on forward scatter versus side scat-
ter cytogram (Fig. 2B). The percentage of live cells shown in
Fig. 2A was 79% of whole cells and this number varied from
72 to 85% in experiments performed in different days. Dou-
blets were eliminated using SSC-W versus SSC-A plot
(Fig. 2C). Moreover HL-60 positive to CD35 and CD11b recep-
tors were gated to identify the neutrophil effector cellpopulation (Fig. 2D), which corresponded to 62.5% of total
live cells (from 45 to 78% in the different experiments).
Finally, a phycoerythrin (PE) fluorescence histogram was
used to evaluate phagocytic activity, which was expressed
as MFI and calculated by setting a Log 4 range over the
whole scale in the PE channel (Fig. 2E).
Focusing on effector cells allowed cleaning off, from the
read out, the fluorescent signal of undifferentiated HL-60, as
demonstrated by the disappearance in the immune serum
histogram shown in Fig. 3A of the double peak present in
Fig. 3B. In this way, enhanced assay sensitivity could be
attained. We believe that the high variability in the number
of live effector cells in the HL-60 population contributes to
the low reproducibility encountered in the classical kOPA.
This variability does not affect the phagocytic activity mea-
surement of our fOPA method, as the fluorescent intensity
derived from undifferentiated cells does not contribute to
the read out of the assay. Indeed, the MFI values obtained
for each dilution of a particular test serum were comparable
irrespective of the proportion of live effector cells.
Several assay conditions were tested to optimize the
method: particularly, different bacteria to neutrophil ratios
(Fig. 4), incubation times and complement concentrations
were tested. Highest phagocytosis rates were achieved
using a ten fold excess of bacteria over phagocytes, 30 min
incubation and 10% baby rabbit complement.
3.3. Confocal microscopy analysis
To assesswhether pHrodo™ labeled GBS Ia bacteria became
brighter once internalized into neutrophils, differentiated
HL-60 cells were incubated with pHrodo™ labeled bacteria in
the presence of an hyperimmune specific serum and comple-
ment for 30 min at 37 °C, and the plasmamembrane of neutro-
phils was stained with Alexa Fluor 488-phalloidin. Z stacks
images of the sample were taken by confocal microscopy.
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17M. Fabbrini et al. / Journal of Immunological Methods 378 (2012) 11–19Neutrophil plasma membrane (green) and pHrodo labeled
bacteria (red) are shown respectively in panels A1 and A2 of
Fig. 5A. The bright field panel (A3) shows the presence of inter-
nalized and non internalized (arrows) bacteria, adhering to the
neutrophil plasma membrane. Finally, the red and green im-
agesmergedwith the bright field image (panel A4) clearly con-
firmed that only internalized bacteria were brightly
fluorescent.
Further analyses by confocal microscopy confirmed that la-
beled GBS bacteria were internalized by differentiated HL-60
cells in the presence of specific antibodies and complement
(Fig. 5B1), whereas no bacteria were found inside the cells of
negative control samples tested with unrelated serum
(Fig. 5B2). These results clearly indicate that bacteria internali-
zation depends both on the presence of functional antibodies
and active rabbit complement.
3.4. Assay sensitivity and speciﬁcity
To test the specificity of the assay, the effect of the tem-
perature on GBS Ia internalization was examined by testing
different dilutions of specific rabbit serum at 4 °C and 37 °C.
Fig. 6 shows the MFI values obtained for each serum dilution
at the two different temperatures. A dramatic reduction of
the phagocytic activity at 4 °C was observed compared to
37 °C, indicating that the pHrodo-based assay was able to
specifically detect internalized GBS bacteria.
Assay specificity and sensitivity were also assessed by
testing sera from rabbits immunized with CRM197-conjugat-
ed polysaccharides Ia or Ib plus Alum and pools of sera from
mice immunized with two trivalent vaccines consisting ofCRM197-conjugated polysaccharides Ia, Ib and III formulated
either in Alum or in MF59. Negative controls comprised sera
from placebo immunized mice and reactions without serum
or containing heat inactivated complement.
As shown in Fig. 7, very high signal-to-background ratios
were obtained for all specific immune sera compared to nega-
tive controls, confirming high specificity of the assay. Remark-
ably, MFI values were inversely proportional to increasing
sera dilutions, indicating that themethod can be used for quan-
titative determination of functional antibodies in test sera.
An arbitrary threshold was established, corresponding to
two times the MFI of negative controls (reaction without
serum, reaction with heat inactivated complement, reaction
18 M. Fabbrini et al. / Journal of Immunological Methods 378 (2012) 11–19with the placebo or pre-immune sera), and the fOPA titer was
calculated as the reciprocal serum dilution yielding threshold
fluorescence values.
To investigate the correlation between the data that can
be obtained using the classical kOPA test and the newly de-
veloped fOPA method, we measured fOPA titers in a panel
of sera displaying a wide range of kOPA titers to GBS Ia. Re-
markably, a good correlation (R2=0.82, pb0.05) between
fOPA and kOPA read outs was observed (Fig. 8). A subset of
sera was also tested against GBS serotype III using the isolate
COH1 and a good correlation between the two methods
(R2=0.85, pb0.05) was obtained also in this case (data not
shown). The data indicate that the fOPA method can be
used to test functional antibodies against different serotypes.
4. Discussion and conclusions
We developed an opsonophagocytosis assay for GBS using
pHrodo™ labeled bacteria. Our method offers several advan-
tages over both killing-based and other fluorescence-based
opsonophagocytic assays.
The most commonly-used fluorophores in OPA assays are
fluorescein (fluorescein, dicarboxyfluorescein, oregon green,
dihydrodichlorofluorescein) or Alexa Fluor derivatives. Flow
cytometry based on those fluorophores can detect cell-
associated fluorescence but cannot distinguish between in-
ternalized and adhering bacteria, necessitating quenching
steps with trypan blue or ethidium bromide to clean out the
background fluorescence of externally bound bacteria. The
pHrodo™-based assay provides sensitive detection without
the need for quenching or washings steps, saving time and
eliminating measurement uncertainty. Indeed, pHrodo™ is
a pH sensitive fluorophore showing a very low fluorescent
signal at the neutral pH of extracellular and cytoplasmic envi-
ronment and a bright fluorescent signal in acidic compart-
ments, such as phago-lysosomes, deriving from the fusion
of phagosome-containing bacteria with lysosomes which oc-
curs immediately after internalization.
As shown by confocal microscopy images, GBS bacteria la-
beled with pHrodo™ exhibit low fluorescence outside the
cell, yet emit a bright red fluorescence after internalization
into the acidic environment of the phagocyte. By determining
whether phagosome containing bacteria mature to phago-
lysosome acidic compartments, the pHrodo™ assay is predic-
tive of phagocytic killing. Several different mechanisms can
lead to bacterial survival after phagocytosis, rendering the
phagocytosis measurement non strictly indicative of patho-
gen clearance. For instance, it has been observed that certain
mycobacteria (e.g. Mycobacterium avium, Mycobacterium
tubercolosis) are not always killed even when enclosed in
phagocytic cells, because the phagosome-lysosome fusion is
not accompanied by the normal acidification that creates
the appropriate conditions for killing (Hornef et al., 2002;
Bellaire et al., 2005; Huynh and Grinstein, 2007). Further,
the phagosome-lysosome fusion may not occur or the phago-
some may not close. OPA using pHrodo™ for bacterial label-
ing permits the detection of efficiently phagocytosed and
killed bacteria, a finding that is further supported by the cor-
relation observed between kOPA and fOPA titers.
The fOPA also presents some improvements over the refer-
ence, killing-based assays. Operational costs related to HL-60differentiation are reduced, as the absolute number of effector
cells is much lower than in kOPA (Guttormsen et al., 2008).
Assay components, such as bacteria and effector cells, can be
more effectively controlled by FACS, immediately before each
experiment. The absolute number of pHrodo labeled bacteria
can be determined by using BD TruCount Tubes. When such a
count is done by comparing biological events to standardized
beads events, it is not affected by bacterial aggregation, as in-
stead occurs in spectrophotometer measurements, usually
used for OPAs. Moreover the use of specific markers of cell dif-
ferentiation allows selecting and analyzing only effective
phagocytes among the whole HL-60 cell population eliminat-
ing one of the major causes of assay variability. Our method
promises to be more easily standardized in comparison with
kOPA methods. It provides a quantifiable read out recorded as
MFI that dramatically reduces the variability due to the opera-
tor and associated with viable bacterial counts, as measure-
ment of killing titers. Finally the fOPA method is faster, i.e.
results are obtained in a single day.
In conclusion, the flow cytometry-based opsonophagocy-
tosis assay described in the present study is a rapid and sen-
sitive method for testing the functionality of serum antibody
responses to GBS and shows specificity and correlation with
killing. The method has the potential, therefore, to become
a viable alternative to the standard killing-based assays,
used as correlate of protection for GBS vaccines.Acknowledgments
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